Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

investigational treatment combines a drug called brentuximab vedotin with a standard chemotherapy treatment made up of cyclophosphamide, doxorubicin, etoposide, and prednisone. This treatment is considered

t-cell lymphoma
prednisone
bone marrow procedure
bone marrow transplant
chop regimen
  • 122 views
  • 01 Jul, 2022
  • 4 locations
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine®

pulse oximetry
classical hodgkin lymphoma
renal function
vinblastine
prednisone
  • 12 views
  • 04 Oct, 2022
  • 6 locations
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive

  • 0 views
  • 27 Jan, 2021
  • 1 location
Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide

adult t-cell leukemia
t-cell lymphoma
prednisone
extranodal nk/t-cell lymphoma, nasal type
angioimmunoblastic t-cell lymphoma
  • 39 views
  • 17 Oct, 2022
  • 2 locations
A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

an antiangiogenic therapy, classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin treatment

paclitaxel
carboplatin
platinum-based chemotherapy
squamous cell carcinoma
cancer chemotherapy
  • 0 views
  • 26 Feb, 2022
BV After Allogeneic Hematopoietic Stem Cell Transplantation (BV-ALLO)

patients. Cumulative incidence of relapse was 37% at 1 year and 59% at 5 years. Brentuximab Vedotin (Bv) is an anti-CD30 antibody-drug conjugate. This drug has shown its efficacy with very

classical hodgkin lymphoma
chemotherapy regimen
brentuximab
lymphoma
autograft
  • 0 views
  • 04 Mar, 2022
  • 6 views
  • 24 May, 2022
  • 7 locations
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL)

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

classical hodgkin lymphoma
vinblastine
large b-cell lymphoma
lymphoma
b-cell lymphoma
  • 0 views
  • 29 Jun, 2022
  • 1 location
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma

romidepsin
monoclonal antibodies
t-cell lymphoma
experimental drug
lymphoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Background Mature T-cell malignancies (TCMs) are a rare group of cancers that usually do not have effective treatments or cures. Because of this, participants with TCMs often relapse and have a poor overall prognosis. This trial is testing if combining several drugs against TCMs can be a more effective. Primary …

romidepsin
prednisone
treatment regimen
measurable disease
flow cytometry
  • 0 views
  • 24 Oct, 2022
  • 1 location